admin 管理员组文章数量: 1086019
2024年3月29日发(作者:手动创建android项目)
人用药品注册技术要求国际协调会(ICH)文件目录
ICH的论题主要分为四类,因此ICH根据论题的类别不同而进行相应的编码分类:
1. “Q”类论题:Q代表QUALITY,指那些与化工和医药,质量保证方面的相关的论
题。Q10都属于这类。
2. “S”类论题:S代表SAFETY,指那些与实验室和动物实验,临床前研究方面的相
关的论题。
3. “E”类论题:E代表EFFICACY,指那些与人类临床研究相关的课题。
4. “M”类论题:M代表MULTIDISCIPLINARY, 指那些不可单独划入以上三个分类
的交叉涉及的论题。同时M又细分为5个小类 :
M1: 常用医学名词 (Med DRA)
M2: 药政信息传递之电子标准
M3: 与临床试验相关的临床前研究时间的安排
M4: 常规技术文件(CTD)
M5: 药物词典的数据要素和标准
一、ICH. 质量部分(Quality) 稳定性
1. Quality质量
2. Q1: Stability稳定性
3. Q1A(R2): Stability Testing of New Drug Substances and Products 新原料药
和制剂的稳定性试验
4. Q1B: Photostability Testing of New Drug Substances and Products 新原料药
和制剂的光稳定性试验
5. Q1C: Stability Testing for New Dosage Forms 新剂型的稳定性试验
6. Q1D: Bracketing and Matrixing Designs for Stability Testing of Drug Substa
nces and Drug Products
原料药和制剂稳定性试验的交叉和矩阵设计 Q1E: Evaluation of Stability Data 稳定
性数据的评估
7. Q1F: Stability Data Package for Registration Applications in Climatic Zones
III and IV
在气候带III和IV,药物注册申请所提供的稳定性数据
8. Q2: Analytical Validation分析验证
9. Q2(R1): Validation of Analytical Procedures: Text and Methodology
分析程序的验证:正文及方法论
10. Q3: Impurities 杂质
11. Q3A(R2): Impurities in New Drug Substances 新原料药中的杂质
12. Q3B(R2): Impurities in New Drug Products (Revised Guideline) 新制剂中
的杂质
13. Q3C(R3): Impurities: Guideline for Residual Solvents 杂质:残留溶剂指南
Impurities: Guideline for Residual Solvents (Maintenance) 杂质:残留溶剂指南
(保留)
PDE for Tetrahydrofuran (in Q3C(R3)) 四氢呋喃的日允许接触剂量
PDE for N-Methylpyrrolidone (in Q3C(R3)) N-甲基吡咯烷酮的日允许接触剂
量
14. Q4: Pharmacopoeias药典
15. Q4A: Pharmacopoeial Harmonisation 药典的协调
16. Q4B: Evaluation and Recommendation of Pharmacopoeial Texts for Use
in the ICH Regions
药典内容的评估及推荐为用于ICH地区
17. Q4B Annex1 Evaluation and Recommendation of Pharmacopoeial Texts
for Use in the ICH Regions
on Residue on Ignition/Sulphated Ash General Chapter
附录1 药典内容的评估及推荐为用于ICH地区 关于灼烧残渣/灰分 常规篇
18. Q4B Annex2 Evaluation and Recommendation of Pharmacopoeial Texts
for Use in the ICH Regions
on Test for Extractable Volume of Parenteral Preparations General Chapter
附录2 药典内容的评估及推荐为用于ICH地区 关于注射剂可提取容量测试 常规篇
19. Q4B Annex3 Evaluation and Recommendation of Pharmacopoeial Texts
for Use in the ICH Regions
on Test for Particulate Contamination: Sub-Visible Particles General Chapter
附录3 药典内容的评估及推荐为用于ICH地区 关于颗粒污染物测试:不溶性微粒 常规
篇
20. Q5: Quality of Biotechnological Products 生物技术制品质量
21. Q5A(R1): Viral Safety Evaluation of Biotechnology Products Derived fro
m Cell Lines of Human or Animal Origin
来源于人或者动物细胞系的生物技术产品的病毒安全性评估
22. Q5B: Quality of Biotechnological Products: Analysis of the Expression Co
nstruct in Cells Used for Production of r-DNA Derived Protein Products
生物技术产品的质量:源于重组DNA的蛋白质产品的生产中所用的细胞中的表达构
建分析
23. Q5C: Quality of Biotechnological Products: Stability Testing of Biotechno
logical/Biological Products
生物技术产品的质量:生物技术/生物产品的稳定性试验
24. Q5D: Derivation and Characterization of Cell Substrates Used for Produc
tion of Biotechnological/Biological Products
用于生产生物技术/生物产品的细胞底物的起源和特征描述
25. Q5E: Comparability of Biotechnological/Biological Products Subject to C
hanges in Their Manufacturing Process
基于不同生产工艺的生物技术产品/生物产品的可比较性
26. Q6: Specifications
规格
27. Q6A: Specifications: Test Procedures and Acceptance Criteria for New Dr
ug Substances and New Drug Products: Chemical Substances (including decision
trees)
质量规格:新原料药和新制剂的检验程序和可接收标准:化学物质(包括决定过程)
28. Q6B: Specifications: Test Procedures and Acceptance Criteria for
29. Biotechnological/Biological Products
质量规格:生物技术/生物产品的检验程序和可接收标准
30. Q7: Good Manufacturing Practices (GMP)
31. Q7A: Good Manufacturing Practice Guide for Active Pharmaceutical Ing
redients 活性药物成份的GMP指南
32. Q8: Pharmaceutical Development
药物研发
33. Annex to Q8
Q8附录
34. Q9: Quality Risk Management
质量风险管理
35. Q10: Pharmaceutical Quality System
药物质量体系
二、ICH.安全性部分(Safety) 致癌试验
1. S1A Guideline on the Need for Carcinogenicity Studies of Pharmaceuticals
药物致癌试验的必要性
2. S1B Testing for Carcinogenicity of Pharmaceuticals 药物致癌试验
3. S1C(R2) Dose Selection for Carcinogenicity Studies of Pharmaceuticals药
物致癌试验的剂量选择
4. S1C’ 药物致癌试验的剂量选择的附件:补充剂量限度和有关注释 遗传毒性
5. S2(R1) Guidance on Genotoxicity Testing and Data Interpretation for
Pharmaceuticals Intended for Human Use 人用药物的遗传毒性试验和数据分析指导
原则
6. S2A药物审评遗传毒性试验的特殊性指导原则
7. S2B遗传毒性:药物遗传毒性试验标准组合 药代
8. S3A Note for Guidance on Toxicokinetics: The Assessment of Systemic
Exposure in Toxicity Studies 毒代动力学指导原则:毒性研究中全身暴露的评价
9. S3B Pharmacokinetics: Guidance for Repeated Dose Tissue Distribution
Studies 药代动力学:重复给药的组织分布研究指导原则 慢性毒性
10. S4 Duration of Chronic Toxicity Testing in Animals (Rodent and Non
Rodent Toxicity Testing) 动物慢性毒性试验的周期(啮齿类和非啮齿类) 生殖毒性
11. S5(R2) Detection of Toxicity to Reproduction for Medicinal Products
and Toxicity to Male Fertility (the Addendum dated November 1995 has been
incorporated into the core guideline in November 2005 )
12. S5A药品的生殖毒性检测
13. S5B雄性生育力毒性 其他
14. S6 Preclinical Safety Evaluation of Biotechnology-Derived
Pharmaceuticals 生物技术药品的临床前安全性试验
15. S7A Safety Pharmacology Studies for Human Pharmaceuticals 人用药物
的安全性药理研究
16. S7B The Non-clinical Evaluation of the Potential for Delayed Ventricular
Repolarization (QT Interval Prolongation) by Human Pharmaceuticals人用药延迟心
室复极化(QT间期延长)潜在作用的非临床评价指导原则
17. S8 Immunotoxicity Studies for Human Pharmaceuticals人类药品的免疫毒
性研究
18. S9 Nonclinical Evaluation for Anticancer Pharmaceuticals抗癌药物的临床
前评价
19. S10 Photosafety Evaluation
三、ICH.临床部分(Efficacy)
1.E1 The Extent of Population Exposure to Assess Clinical Safety for Drugs
Intended for Long-Term Treatment of Non-Life-Threatening Conditions 评价临床
长期给药方案 的安全性
2.E2A Definitions and Standards for Expedited Reporting 快速报告的定义和标
准
3.E2B(R3) Data Elements for Transmission of Individual Case Safety Reports个
体病例安全性报告传递的数据要素
4.E2C Periodic Benefit-Risk Evaluation Report 上市药品定期安全性更新报告
5.E2D Post-Approval Safety Data Management: Definitions and Standards for
Expedited Reporting批准后安全性数据管理:快速报告的定义和标准
6.E2E Pharmacovigilance Planning药物警戒计划
7. E2F Development Safety Update Report
8.E3 Structure and Content of Clinical Study Reports 临床研究报告的结构与内
容
9.E4 Dose-Response Information to Support Drug Registration 新药注册所需量
-效关系的资料
10.E5(R1) Ethnic Factors in the Acceptability of Foreign Clinical Data 对国外临
床研究资料的种族因素的可接受性
11.E6(R1) Good Clinical Practice: Consolidated Guideline 药品临床研究规范
(GCP)一致性指导原则
12.E7 Studies in Support of Special Populations: Geriatrics 老年人群的临床研究
13.E8 General Considerations for Clinical Trials 临床试验的一般考虑
14.E9 Statistical Principles for Clinical Trials 临床试验统计原则
15.E10 Choice of Control Group and Related Issues in Clinical Trials 对照组的
选择
16.E11 Clinical Investigation of Medicinal Products in the Pediatric Population
儿童人群的临床研究
17.E12按治疗分类的各类药物临床评价
E12 Principles for Clinical Evaluation of New Antihypertensive Drugs
18.E14 The Clinical Evaluation of QT/QTc Interval Prolongation and
Proarrhythmic
Potential for Non-Antiarrhythmic Drugs 非抗心律失常药物致QT/QTc间期延长及
潜在心律失常作用的临床评价
19.E15 Definitions for Genomic Biomarkers, Pharmacogenomics,
Pharmacogenetics, Genomic Data and Sample Coding Categories
20.E16 Biomarkers Related to Drug or Biotechnology Product Development:
Context, Structure and Format of Qualification Submissions
四、ICH.综合部分 (Multidisciplinary)
1. M1医学术语Med DRA
2. M2 Electronic Transmission of Individual Case Safety Reports Message
Specification (ICH ICSR DTD Version 2.1) companion document to E2B(R3)
注册资料传递所需的电子代码
3. M3 Guidance on Nonclinical Safety Studies for the Conduct of Human
Clinical Trials and Marketing Authorization for Pharmaceuticals
与临床研究有关的临床前研究的时间安排
4. M4 Organisation of the Common Technical Document for the Registration
of Pharmaceuticals for Human Use (Edited with Numbering and Section Header
Changes, September 2002). Including the Annex : the Granularity Document
(Revised November 2003).
CTD(common technical document)(包括CTD、CTD-Q、CTD-S、CTD-E和eCTD)
药品词汇的数据要素和标准
5. M4Q (R1) The Common Technical Document for the Registration of
Pharmaceuticals for Human Use: Quality (Edited with Numbering and Section
Header Changes, September 2002)
6. M4S (R2) The Common Technical Document for the Registration of
Pharmaceuticals for Human Use: Safety (Edited with Numbering and Section
Header Changes, September 2002)
7. M4E (R1) The Common Technical Document for the Registration of
Pharmaceuticals for Human Use: Efficacy (Edited with Numbering and Section
Header Changes, September 2002)
8. M7 Assessment and Control of DNA Reactive (Mutagenic) Impurities in
Pharmaceuticals to Limit Potential Carcinogenic Risk
Reference:
1. 《ICH 药品注册的国际要求》
2.
3. /health/Health/yx/yao/2007-08-07/
版权声明:本文标题:ICH 指导原则文件目录(中英文) 内容由网友自发贡献,该文观点仅代表作者本人, 转载请联系作者并注明出处:http://www.roclinux.cn/b/1711722483a607482.html, 本站仅提供信息存储空间服务,不拥有所有权,不承担相关法律责任。如发现本站有涉嫌抄袭侵权/违法违规的内容,一经查实,本站将立刻删除。
发表评论